BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17906611)

  • 1. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases.
    Hansen A; Lipsky PE; Dörner T
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):561-9. PubMed ID: 17906611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype.
    Smedby KE; Hjalgrim H; Askling J; Chang ET; Gregersen H; Porwit-MacDonald A; Sundström C; Akerman M; Melbye M; Glimelius B; Adami HO
    J Natl Cancer Inst; 2006 Jan; 98(1):51-60. PubMed ID: 16391371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of lymphoma development in autoimmune diseases: a meta-analysis.
    Zintzaras E; Voulgarelis M; Moutsopoulos HM
    Arch Intern Med; 2005 Nov; 165(20):2337-44. PubMed ID: 16287762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics.
    Smedby KE; Baecklund E; Askling J
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2069-77. PubMed ID: 17119030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary tumours in Sjögren's syndrome.
    Kovács L; Szodoray P; Kiss E
    Autoimmun Rev; 2010 Feb; 9(4):203-6. PubMed ID: 19602455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell depletion for rheumatic diseases: where are we?
    Cohen SB
    MedGenMed; 2005 Jun; 7(2):72. PubMed ID: 16369450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis.
    Löfström B; Backlin C; Pettersson T; Lundberg IE; Baecklund E
    J Rheumatol; 2011 Sep; 38(9):1891-7. PubMed ID: 21724695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell depletion therapy in rheumatic disease.
    Edwards JC; Cambridge G; Leandro MJ
    Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):915-28. PubMed ID: 16980214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.
    Dias C; Isenberg DA
    Nat Rev Rheumatol; 2011 Jun; 7(6):360-8. PubMed ID: 21637317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple specificities of autoantibodies against hnRNP A/B proteins in systemic rheumatic diseases and hnRNP L as an associated novel autoantigen.
    Siapka S; Patrinou-Georgoula M; Vlachoyiannopoulos PG; Guialis A
    Autoimmunity; 2007 May; 40(3):223-33. PubMed ID: 17453722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias.
    Tzioufas AG; Voulgarelis M
    Best Pract Res Clin Rheumatol; 2007 Dec; 21(6):989-1010. PubMed ID: 18068857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell epitopes of the heterogeneous nuclear ribonucleoprotein A2: identification of a new specific antibody marker for active lupus disease.
    Schett G; Dumortier H; Hoefler E; Muller S; Steiner G
    Ann Rheum Dis; 2009 May; 68(5):729-35. PubMed ID: 18495733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignancy and autoimmunity.
    Bernatsky S; Ramsey-Goldman R; Clarke A
    Curr Opin Rheumatol; 2006 Mar; 18(2):129-34. PubMed ID: 16462517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development.
    Manoussakis MN; Boiu S; Korkolopoulou P; Kapsogeorgou EK; Kavantzas N; Ziakas P; Patsouris E; Moutsopoulos HM
    Arthritis Rheum; 2007 Dec; 56(12):3977-88. PubMed ID: 18050195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphomas in patients with Sjögren's syndrome: review of the literature and physiopathologic hypothesis.
    Mariette X
    Leuk Lymphoma; 1999 Mar; 33(1-2):93-9. PubMed ID: 10194125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking as a trigger for inflammatory rheumatic diseases.
    Klareskog L; Padyukov L; Alfredsson L
    Curr Opin Rheumatol; 2007 Jan; 19(1):49-54. PubMed ID: 17143096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study of 82 cases of canine lymphoma in Austria based on the Working Formulation and immunophenotyping.
    Guija de Arespacochaga A; Schwendenwein I; Weissenböck H
    J Comp Pathol; 2007; 136(2-3):186-92. PubMed ID: 17416237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management.
    Peveling-Oberhag J; Arcaini L; Hansmann ML; Zeuzem S
    J Hepatol; 2013 Jul; 59(1):169-77. PubMed ID: 23542089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?
    Molloy ES; Calabrese LH
    Autoimmun Rev; 2008 Dec; 8(2):144-6. PubMed ID: 18700172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.